$UTHR

ROTHBLATT MARTINE A sold $5.0M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $526.73 ($523.15–$532.49, $5.00M total) across 10 trades on 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Jul 28, 2026, 10:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 28, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
high confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity, but this single disclosure does not provide new operational, clinical, regulatory, or financial guidance for United Therapeutics.

02

Market read

A $5.0M insider sale by the CEO under a 10b5-1 plan is disclosed, which may cause minor sentiment noise but lacks fundamental new information.

03

What to watch

The filing specifies indirect holdings and multiple small trades across the day; without context on total planned sales or remaining plan size, interpreting intent is limited.

Relevance 5/10Novelty 4/10Timing: today’s SEC Form 4 insider-sale disclosure (filed 2026-07-28)

Background

The article is an SEC Form 4 insider transaction disclosure for United Therapeutics, reported by CEO chairperson Martine A. Rothblatt, with sales executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$UTHRNeutralHigh confidence
Context

United Therapeutics disclosed a Form 4 showing CEO chairperson Rothblatt sold $5.0M of UTHR via an open-market sale under a 10b5-1 plan on 2026-07-28.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst implied by the filing alone.

Evidence & confidence

The filing provides transaction size, price range, and that it was executed under a pre-arranged Rule 10b5-1 plan, which typically indicates routine diversification rather than new negative information.

Market effects

Minimal. Insider-sale filings rarely change sector fundamentals for biotech/pharma without accompanying operational or regulatory news.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, the market may overreact; the transaction could be routine liquidity management rather than a bearish signal.

Key entities

  • UNITED THERAPEUTICS Corp

    Subject of the Form 4 insider transaction disclosure.

  • ROTHBLATT MARTINE A

    Chairperson and CEO reporting the sale of indirect holdings.

  • Rule 10b5-1 plan

    Pre-arranged plan noted as Yes, reducing interpretive signal.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.